Abstract:Abstract Context.—Primary pulmonary neuroendocrine tumors are traditionally classified into 3 major types: typical carcinoid (TC), atypical carcinoid (AC), and large cell neuroendocrine carcinoma (LC) or small cell neuroendocrine carcinoma (SC). Confusion arises frequently regarding the malignant nature of TC and the morphologic differentiation between AC and LC or SC. Objective.—To provide clinicopathologic evidence to streamline and clarify the histomorphologic criteria for this group of tumors, emphasizing the prognostic implications. Patients.—To minimize variability in diagnostic criteria and treatment plans, we analyzed a group of patients whose diagnosis and treatment occurred at a single institution. We reviewed 234 cases of primary pulmonary neuroendocrine tumors and thoroughly studied 50 cases of resected tumors from 1986 to 1995. Results.—On the basis of morphologic characteristics and biologic behaviors of the tumors, we agree with many previous investigators that these tumors are all malignant and potentially aggressive. Based on our accumulated data, we have modified Gould criteria and reclassified these tumors into 5 types: (1) well-differentiated neuroendocrine carcinoma (otherwise called TC) (14 cases, with less than 1 mitosis per 10 high-power fields [HPF] with or without minimal necrosis); (2) moderately differentiated neuroendocrine carcinoma (otherwise called low-grade AC) (6 cases, with less than 10 mitoses per 10 HPF and necrosis evident at high magnification); (3) poorly differentiated neuroendocrine carcinoma (otherwise called high-grade AC) (10 cases, with more than 10 mitoses per 10 HPF and necrosis evident at low-power magnification); (4) undifferentiated LC (5 cases, with more than 30 mitoses per 10 HPF and marked necrosis); and (5) undifferentiated SC (15 cases, with more than 30 mitoses per 10 HPF and marked necrosis). The 5-year survival rates were 93%, 83%, 70%, 60%, and 40% for well, moderately, and poorly differentiated, and undifferentiated large cell and small cell neuroendocrine carcinomas, respectively. We found nodal metastasis in 28% of TC in this retrospective review, a figure higher than previously recorded. Conclusion.—Using a grading system and terms comparable to those used for many years and used for neuroendocrine tumors elsewhere in the body, we found that classification of pulmonary neuroendocrine carcinomas as well, moderately, poorly differentiated, or undifferentiated provides prognostic information and avoids misleading terms and concepts. This facilitates communication between pathologists and clinicians and thereby improves diagnosis and management of the patient.

Relation Between Hash1 and Pulmonary Neuroendocrine Tumors

Expression and Clinicopathologic Significance of Human Achaete-scute Homolog 1 in Pulmonary Neuroendocrine Tumors

Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis

Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma.

Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma.

Disparity in Clinical Outcomes Between Pure and Combined Pulmonary Large-Cell Neuroendocrine Carcinoma: A Multi-Center Retrospective Study.

Expression of SRF, E-cadherin and β-catenin in hepatocellular carcinoma and its clinical significances

Pulmonary Neuroendocrine Carcinomas

Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma

Characteristics and Prognosis of 127 Cases with Bronchopulmonary Neuroendocrine Tumors

Clinicopathological Significance of Expressions of C-Myc and E2F1 Proteins in Neuroendocrine Lung Carcinoma

Primary and metastatic hepatic neuroendocrine carcinoma: a clinicopathological study

Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas

[Study on the Specific Expressions of P53, Bcl-2 and C-Myc in Non-Small Cell Lung Cancer with Neuroendocrine Differentiation].

Pulmonary Neuroendocrine Carcinomas - A Review Of 234 Cases And A Statistical Analysis Of 50 Cases Treated At One Institution Using A Simple Clinicopathologic Classification

Clinicopathological Characteristics of the primary and metastatic Hepatic Neuroendocrine Tumors and the relevant Prognosis-Related Factors: A Retrospective Study of 81 Cases in a Single Chinese Center.

Expression of Heparanase-1 in malignant pheochromocytomas

The Research Status of Bronchopulmonary Neuroendocrine Tumor

Prognostic Value of PD-L1 and PD-1 Expression in Pulmonary Neuroendocrine Tumors.

Epigenetic modifications of histone h4 in lung neuroendocrine tumors

Clinicopathological Significance of Expression of Fragile Histidine Triad Protein in Neuroendocrine Lung Carcinoma